Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group
To the editor: DNA methyltransferase-inhibiting azanucleosides have become a mainstay of treatment of myeloid neoplasms in adult patients,[1][1] with 5-azacytidine (azacitidine) being the agent in broadest clinical use. Although not curative, treatment with azacitidine achieves hematologic
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
2 April 2015
|
| In: |
Blood
Year: 2015, Volume: 125, Issue: 14, Pages: 2311-2313 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood-2015-01-619734 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1182/blood-2015-01-619734 Verlag, kostenfrei, Volltext: http://www.bloodjournal.org/content/125/14/2311 
|
| Author Notes: | Annamaria Cseh, Charlotte M. Niemeyer, Ayami Yoshimi, Michael Dworzak, Henrik Hasle, Marry M. van den Heuvel-Eibrink, Franco Locatelli, Riccardo Masetti, Markus Schmugge, Ute Groß-Wieltsch, Andrea Candás, Andreas E. Kulozik, Lale Olcay, Meinolf Suttorp, Ingrid Furlan, Brigitte Strahm, Christian Flotho |
| Summary: | To the editor: DNA methyltransferase-inhibiting azanucleosides have become a mainstay of treatment of myeloid neoplasms in adult patients,[1][1] with 5-azacytidine (azacitidine) being the agent in broadest clinical use. Although not curative, treatment with azacitidine achieves hematologic |
|---|---|
| Item Description: | Gesehen am 13.07.2017 |
| Physical Description: | Online Resource |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood-2015-01-619734 |